ZNTL
Zentalis Pharmaceuticals, Inc.1.3800
-0.0200-1.43%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
99.71MP/E (TTM)
-Basic EPS (TTM)
-2.08Dividend Yield
0%Recent Filings
10-K
8-K
8-K
Azenosertib milestones set for 2026
Zentalis provided a corporate update on January 6, 2026, highlighting 2025 accomplishments like completing DENALI Part 2a enrollment and FDA alignment on ASPENOVA Phase 3 design for azenosertib in Cyclin E1-positive PROC. Cash of $280.7M as of September 30 funds runway into late 2027. Key milestones ahead: dose confirmation and ASPENOVA start in H1 2026, DENALI Part 2 topline by year-end. Forward-looking statements carry risks.
8-K
Zentalis buys back shares
Zentalis repurchased 7,500,000 shares from Matrix Capital at $1.33 each—below the $1.40 close on December 12—closing December 15, 2025, amid Matrix's fund wind-down. Board shrank to six after Karan Takhar's immediate resignation that day, with no disagreements noted. Cash runway holds into late 2027.
10-Q
Q3 FY2025 results
Zentalis narrowed Q3 FY2025 losses to $26.7M from $40.2M y/y, as R&D expenses dropped 38% to $23.0M (derived) from cuts in personnel and clinical costs post-January restructuring that trimmed headcount 40%. Operating loss improved to $33.7M from $51.4M y/y, with diluted EPS at -$0.37 versus -$0.56; YTD net loss shrank to $101.8M from $118.4M despite $7.8M restructuring charge, reconciling to 71.9M diluted shares. Cash burn eased to $27.0M (derived) for Q3, ending with $39.1M cash plus $239.2M marketable securities and no debt. R&D focused on azenosertib external costs at $12.6M. Clinical trials may fail to meet FDA standards.
ARTL
Artelo Biosciences, Inc.
1.84+0.01
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ENTO
Entero Therapeutics Inc.
2.99+0.15
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
NUVL
Nuvalent, Inc.
102.63-2.34
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
PTHS
Pelthos Therapeutics Inc.
21.83-0.42
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZLAB
Zai Lab Limited
17.00-0.34